Screener
Rapport Therapeutics, Inc. RAPP Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the six monthsended June 30, 2026 | For the six monthsended June 30, 2025 |
|---|---|---|
| Payment of deferred offering costs | (454) | (63) |
| Proceeds from exercise of stock options | 2,401 | 6 |
| Repurchase of unvested restricted common stock | (5) | (1) |
| Net cash provided by (used in) financing activities | 1,942 | (58) |
| Net increase in cash, cash equivalents, and restricted cash | 10,967 | (1,738) |
| Cash, cash equivalents, and restricted cash at beginning of period | 52,750 | 56,910 |
| Cash, cash equivalents, and restricted cash at end of period | $63,717 | $55,172 |
| Supplemental disclosure for noncash investing and financing activities: |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s financing cash flow?
- Rapport Therapeutics, Inc. (RAPP) reported financing cash flow of $1.41M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Rapport Therapeutics, Inc.'s financing cash flow increased by 2339.7% year-over-year, from -$63K to $1.41M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Rapport Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude